US Penny Stocks To Consider In February 2025

As of February 2025, major U.S. stock indexes are nearing record highs, buoyed by recent economic data and policy developments that have fostered optimism among investors. Despite the vintage connotation of "penny stocks," these investments in smaller or newer companies continue to hold potential for those seeking affordability and growth. When supported by strong financials, penny stocks can offer a blend of opportunity and stability, making them an intriguing option for investors looking to uncover hidden value in the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8964	$6.3M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$131.87M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.81	$46.67M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.84	$86.14M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.395	$46.2M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8977	$80.89M	★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)	$1.40	$24.65M	★★★★★☆
PHX Minerals (NYSE:PHX)	$4.17	$154.8M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.61	$382.26M	★★★★☆☆

Click here to see the full list of 710 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Organogenesis Holdings (NasdaqCM:ORGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets in the United States, with a market cap of $460.16 million.

Operations: The company generates revenue of $455.04 million from its regenerative medicine segment.

Market Cap: $460.16M

Organogenesis Holdings Inc., a regenerative medicine company, has shown resilience despite being currently unprofitable. The company maintains a strong financial position with short-term assets of US$238.5 million exceeding both its short-term and long-term liabilities, and more cash than total debt. Recent strategic moves include a share repurchase program funded by proceeds from preferred stock sales and plans to expand manufacturing capacity in Rhode Island, contingent on tax incentives. Although significant insider selling occurred recently, the management team is experienced with an average tenure of 7.4 years, supporting potential future growth opportunities in the sector.

• Jump into the full analysis health report here for a deeper understanding of Organogenesis Holdings.
• Understand Organogenesis Holdings' earnings outlook by examining our growth report.

ThredUp (NasdaqGS:TDUP)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: ThredUp Inc. operates an online resale platform for secondhand clothing in the United States and internationally, with a market cap of $302.71 million.

Operations: The company's revenue segment consists of $313.76 million from online retailers.

Market Cap: $302.71M

ThredUp Inc., an online resale platform, faces challenges typical of penny stocks with its unprofitable status and increased losses over the past five years at 9.8% annually. Despite this, the company maintains a solid cash position, having more cash than total debt and a sufficient runway for over three years based on current free cash flow trends. However, its short-term liabilities exceed short-term assets by US$3 million. The management team is seasoned with an average tenure of 5.3 years, which may provide stability amidst high share price volatility and negative return on equity at -100.9%.

• Click to explore a detailed breakdown of our findings in ThredUp's financial health report.
• Gain insights into ThredUp's future direction by reviewing our growth report.

United States Antimony (NYSEAM:UAMY)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: United States Antimony Corporation engages in the production and sale of antimony, silver, gold, precious metals, and zeolite products in the United States and Canada, with a market cap of $208.20 million.

Operations: The company's revenue is primarily derived from its Antimony operations in the United States ($6.44 million), Zeolite products ($2.80 million), and Precious Metals ($0.49 million).

Market Cap: $208.2M

United States Antimony Corporation, with a market cap of US$208.20 million, is navigating the typical challenges of penny stocks, including unprofitability and increased volatility. Its management team and board are relatively new, with average tenures of 0.8 and 2.2 years respectively, potentially impacting strategic stability. Despite these challenges, the company has a strong financial position with short-term assets exceeding both long-term and short-term liabilities significantly (US$15M vs US$2.2M and US$2.4M). Recent activities include filing a US$100 million shelf registration to support future financing needs while maintaining sufficient cash runway for over three years if current trends persist.

• Dive into the specifics of United States Antimony here with our thorough balance sheet health report.
• Learn about United States Antimony's future growth trajectory here.

Make It Happen

• Take a closer look at our US Penny Stocks list of 710 companies by clicking here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com